Actively Recruiting

Phase 4
Age: 55Years +
All Genders
Healthy Volunteers
NCT06568549

Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.

Led by Mayo Clinic · Updated on 2026-03-20

350

Participants Needed

3

Research Sites

302 weeks

Total Duration

On this page

Sponsors

M

Mayo Clinic

Lead Sponsor

T

Transplant Genomics, Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this research is to determine the safety and efficacy of withdrawing MMF (Mycophenolate Mofetil) in kidney transplant recipients who are 55 years or older at the time of receiving a kidney transplant. We are comparing them to patients who receive the standard of care Mycophenolate Mofetil.

CONDITIONS

Official Title

Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.

Who Can Participate

Age: 55Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Solitary kidney transplant recipient aged over 55 years, with at most one prior solitary kidney transplant
  • No other solid organ transplant; autologous stem cell transplant recipients are allowed
  • HIV negative
  • Currently on tacrolimus and Mycophenolate Mofetil (MMF) or Myfortic at consent; prednisone use optional per local care
  • Patients randomized to MMF withdrawal will start prednisone 5mg/day at 4 months
  • Use of other maintenance immunosuppressants (cyclosporine, azathioprine, belatacept, sirolimus) is not allowed
Not Eligible

You will not qualify if you...

  • Donor-specific antibody (DSA) with MFI greater than 2000 at time of transplant
  • Calculated panel reactive antibody (cPRA) above 80% (based on MFI >2000) at time of transplant
  • Acute rejection episode (greater than borderline) at any time before 4 months or signs of rejection at 4-month biopsy
  • Presence of de novo DSA
  • Not on tacrolimus at time of randomization (placed in non-randomized group)
  • History of holding or temporarily stopping MMF or Myfortic due to clinical reasons does not exclude randomization
  • Any clinically significant acute or chronic medical condition or physical exam finding making participation unsafe or limiting assessments

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Mayo Clinic

Phoenix, Arizona, United States, 85054

Actively Recruiting

2

Mayo Clinic

Jacksonville, Florida, United States, 32224

Actively Recruiting

3

Mayo Clinic

Rochester, Minnesota, United States, 55905

Actively Recruiting

Loading map...

Research Team

N

Nong Yowe Braaten, LPN

CONTACT

E

Esma Kesik, M.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here